How IPF, Chronic ILD with Worsening Fibrosis, and SSc-ILD Affect the Lungs Hero

FOR YOUR
JOURNEY
AHEAD, THERE’S OFEV.

Keep moving forward with OFEV® (nintedanib) capsules, the only twice-daily prescription medication approved to:

  • treat adults with a lung disease called idiopathic pulmonary fibrosis (IPF).
  • treat adults with a long lasting (chronic) interstitial lung disease in which lung fibrosis continues to worsen (progress).
  • slow the rate of decline in lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD) (also known as scleroderma-associated ILD).

It is not known if OFEV is safe and effective in children.

Why
Ofev?

OFEV prescription icon

First approved by the FDA in 2014 as a treatment for adults with IPF.

lung decline rate icon

In 2019, OFEV became the first FDA-approved therapy to slow the rate of decline in lung function in adults with SSc-ILD.

people icon

Today, OFEV is also the first FDA-approved treatment for adults with a chronic ILD with worsening fibrosis.